U.S. Cancer Biopsy Market Size, Share & Trends Report

U.S. Cancer Biopsy Market Size, Share & Trends Analysis Report By Type (Fine-needle Aspiration, Core, Surgical, Skin Biopsy/Punch Biopsy), By Application, By Site, And Segment Forecasts, 2021 - 2028

  • Published Date: Jul, 2021
  • Base Year for Estimate: 2020
  • Report ID: GVR-4-68039-467-3
  • Format: Electronic (PDF)
  • Historical Data: 2017 - 2019
  • Number of Pages: 143

Table of Contents

Chapter 1 Methodology And Scope
                 1.1 Research Methodology
                 1.2 Research Assumptions
                      1.2.1 Estimates and forecast timeline
                 1.3 Research Methodology
                 1.4 Information Procurement
                      1.4.1 Purchased database
                      1.4.2 GVR’s internal database
                      1.4.3 Secondary sources
                           1.4.3.1 Primary research
                      1.4.4 Details of primary research
                 1.5 Information or Data Analysis
                      1.5.1 Data analysis models
                           1.5.1.1 End - use landscape assessment
                           1.5.1.2 Market origin assessment
                           1.5.1.3 Oncology diagnosis: market competition analysis
                 1.6 Market Formulation and Validation
                 1.7 Model Details
                      1.7.1 Commodity Flow Analysis
                           1.7.1.1 Approach 1: Commodity flow approach
                           1.7.1.2 Approach 2: Country-wise market estimation using bottom-up approach
                 1.8 U.S. Market: CAGR Calculation
                 1.9 List of Secondary Sources
                 1.10 List of Primary Sources
Chapter 2 Executive Summary
Chapter 3 Market Variables, Trends, And Scope
                 3.1 Cancer Medical Tourism Within & Outside the U.S.
                 3.2 Market Driver Analysis
                      3.2.1 Advent of liquid biopsy
                      3.2.2 Transition of novel oncology diagnostics from bench to clinics
                      3.2.3 Advancements in quality and payment pertaining to genetic cancer tests
                 3.3 Market Restraint Analysis
                      3.3.1 Risks associated with biopsy procedures
                      3.3.2 Technical and clinical challenges
                 3.4 Market Opportunity Analysis
                      3.4.1 Integral role of biopsies in oncology companion diagnostics
                      3.4.2 Increase in the demand for biopsies in translational research
                 3.5 Market Threat Analysis
                      3.5.1 Risk associated with repeat biopsy procedures
Chapter 4 Business Environment Analysis
                 4.1 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
                 4.2 Porter’s Five Forces Analysis
Chapter 5 Supply Chain Analysis
                 5.1 Sample Collection (List of biobanks/center)
                 5.2 Sample Processing (List of vendors)
Chapter 6 Cost/ Pricing Analysis
                 6.1 Biopsy Cost
                      6.1.1 By Indication
                           6.1.1.1 Typical biopsy costs for patients not covered by health insurance, U.S.
                      6.1.2 By Type/Method
                 6.2 Key Factors Influencing the Cost
                 6.3 Costs of Cancer Management
                      6.3.1 Pharma versus diagnostics price analysis for cancer care
                      6.3.2 U.S. Expenditures for cancer by source of payment
                           6.3.2.1 expenditures for cancer care by year & cancer site, USD Million, 2010 - 2018
Chapter 7 Reimbursement & Regulatory Analysis
                 7.1 Regulatory Framework: U.S. Cancer Biopsy Market
                 7.2 Reimbursement Framework: U.S. Cancer Biopsy Market
Chapter 8 Challenges/Restraints/Complications Analysis
                 8.1 Challenges/Restraints/Complications Analysis
                      8.1.1 By site (organ)
                      8.1.2 By method
Chapter 9 U.S. Cancer Biopsy Market: Type Business Analysis
                 9.1 Market: Type Movement Analysis
                 9.2 Market: Comparative Analysis of Biopsy Type
                 9.3 Fine - Needle Aspiration
                      9.3.1 Market estimates and forecasts, 2017 - 2028 (USD Million)
                           9.3.1.1 Market estimates and forecasts for pharma - use, 2017 - 2028 (USD Million)
                           9.3.1.2 Market estimates and forecasts for clinical - use, 2017 - 2028 (USD Million)
                 9.4 Core Needle Biopsy (CNB)
                      9.4.1 Market estimates and forecasts, 2017 - 2028 (USD Million)
                           9.4.1.1 Market estimates and forecasts for pharma - use, 2017 - 2028 (USD Million)
                           9.4.1.2 Market estimates and forecasts for clinical - use, 2017 - 2028 (USD Million)
                 9.5 Cancer Surgical Biopsy
                      9.5.1 Market estimates and forecasts, 2017 - 2028 (USD Million)
                           9.5.1.1 Market estimates and forecasts for pharma - use, 2017 - 2028 (USD Million)
                           9.5.1.2 Market estimates and forecasts for clinical - use, 2017 - 2028 (USD Million)
                 9.6 Skin Biopsy /Punch Biopsy
                      9.6.1 Market estimates and forecasts, 2017 - 2028 (USD Million)
                           9.6.1.1 Market estimates and forecasts for pharma - use, 2017 - 2028 (USD Million)
                           9.6.1.2 Market estimates and forecasts for clinical - use, 2017 - 2028 (USD Million)
                 9.7 Others
                      9.7.1 Market estimates and forecasts for other types, 2017 - 2028 (USD Million)
                           9.7.1.1 Market estimates and forecasts for pharma - use, 2017 - 2028 (USD Million)
                           9.7.1.2 Market estimates and forecasts for clinical - use, 2017 - 2028 (USD Million)
Chapter 10 U.S. Cancer Biopsy Market: Site (Organ) Business Analysis
                 10.1 Market: Site (Organ) Movement Analysis
                 10.2 Breast
                      10.2.1 Market estimates and forecasts for breast, 2017 - 2028 (USD Million)
                 10.3 Thyroid
                      10.3.1 Market estimates and forecasts for thyroid, 2017 - 2028 (USD Million)
                 10.4 Uterus & Cervix
                      10.4.1 Market estimates and forecasts for uterus & cervix, 2017 - 2028 (USD Million)
                 10.5 Lung
                      10.5.1 Market estimates and forecasts for lung, 2017 - 2028 (USD Million)
                 10.6 Prostate
                      10.6.1 Market estimates and forecasts for prostate, 2017 - 2028 (USD Million)
                 10.7 Bladder
                      10.7.1 Market estimates and forecasts for bladder, 2017 - 2028 (USD Million)
                 10.8 Kidney
                      10.8.1 Market estimates and forecasts for kidney, 2017 - 2028 (USD Million)
                 10.9 Liver
                      10.9.1 Market estimates and forecasts for liver, 2017 - 2028 (USD Million)
                 10.10 Pancreas
                      10.10.1 Market estimates and forecasts for pancreas, 2017 - 2028 (USD Million)
                 10.11 Other Sites
                      10.11.1 Market estimates and forecasts for other sites, 2017 - 2028 (USD Million)
Chapter 11 U.S. Cancer Biopsy Market: Application Business Analysis
                 11.1 Market: Application Movement Analysis
                 11.2 Screening & Monitoring
                      11.2.1 Market estimates and forecasts for screening & monitoring, 2017 - 2028 (USD Million)
                 11.3 Diagnostics
                      11.3.1 Market estimates and forecasts for diagnostics, 2017 - 2028 (USD Million)
                 11.4 Investigational & Translational Research
                      11.4.1 Market estimates and forecasts for investigational & translational research, 2017 - 2028 (USD Million)
                 11.5 Pharma & Biopharma Discovery & Development
                      11.5.1 Market estimates and forecasts for pharma & biopharma discovery & development, 2017 - 2028 (USD Million)
Chapter 12 Company Profiles
                 12.1 Company Profiles
                      12.1.1 BD (Becton, Dickinson and Company)
                           12.1.1.1 Company overview
                           12.1.1.2 Financial performance
                           12.1.1.3 Product benchmarking
                           12.1.1.4 Strategic initiatives
                      12.1.2 IZI Medical Products
                           12.1.2.1 Company overview
                           12.1.2.2 Product benchmarking
                           12.1.2.3 Strategic initiatives
                      12.1.3 Johnson & Johnson Services
                           12.1.3.1 Company overview
                           12.1.3.2 DePuy Synthes
                                12.1.3.2.1 Company overview
                           12.1.3.3 Ethicon, Inc.
                                12.1.3.3.1 Company overview
                           12.1.3.4 Financial performance
                           12.1.3.5 Product benchmarking
                      12.1.4 Argon Medical
                           12.1.4.1 Company overview
                           12.1.4.2 Product benchmarking
                      12.1.5 Cook Medical
                           12.1.5.4 Company overview
                           12.1.5.5 Product benchmarking
                      12.1.6 Spectra Medical Devices, Inc.
                           12.1.6.1 Company overview
                           12.1.6.2 Product benchmarking
                      12.1.7 Medtronic plc
                           12.1.7.1 Company overview
                           12.1.7.2 Financial performance
                           12.1.7.3 Product benchmarking
                      12.1.8 Boston Scientific Corporations
                           12.1.8.1 Company overview
                           12.1.8.2 Financial performance
                           12.1.8.3 Product benchmarking
                           12.1.8.4 Strategic initiatives
                      12.1.9 Conmed Corporation
                           12.1.9.1 Company overview
                           12.1.9.2 Financial performance
                           12.1.9.3 Product benchmarking
                      12.1.10 Inrad, Inc.
                           12.1.10.1 Company overview
                           12.1.10.2 Product benchmarking


List of Tables

Table 1 List of secondary sources
Table 2 Reasons for the popularity of oncology tourism in some countries
Table 3 Common types of oncology tourism treatments
Table 4 Liquid biopsy developing or commercializing companies
Table 5 Average pricing analysis: Biopsy to indication
Table 6 Average pricing analysis: Biopsy to indication
Table 7 Expenditures for cancer care by year & cancer site, USD Million, 2010 - 2018
Table 8 List of cleared/approved companion diagnostic devices (In vitro and imaging tools)
Table 9 Types of insurance coverage
Table 10 Policy structure types issued by private payers and Medicare
Table 11 Coverage policies for ctDNA
Table 12 CPT codes for minimally invasive prostate procedures
Table 13 CPT codes for office visits - new & established patient
Table 14 Surgical biopsy: Feasibility analysis across cancer diagnosis
Table 15 Comparative analysis of traditional and liquid liver biopsies
Table 16 U.S. cancer biopsy market, by type, 2017 - 2028 (USD Million)
Table 17 U.S. cancer biopsy market, by fine-needle aspiration, 2017 - 2028 (USD Million)
Table 18 U.S. cancer biopsy market, by core needle biopsy, 2017 - 2028 (USD Million)
Table 19 U.S. cancer biopsy market, by surgical biopsy, 2017 - 2028 (USD Million)
Table 20 U.S. cancer biopsy market, by skin biopsy, 2017 - 2028 (USD Million)
Table 21 U.S. cancer biopsy market, by other biopsies, 2017 - 2028 (USD Million)
Table 22 U.S. cancer biopsy market, by site (organ), 2017 - 2028 (USD Million)
Table 23 U.S. cancer biopsy market, by application (cause), 2017 - 2028 (USD Million)


List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 End - use landscape: cancer biopsy product penetration
Fig. 5 Cancer biopsy: Market origin/parent market assessment
Fig. 6 Market competition analysis: early diagnosis industry sector
Fig. 7 Market formulation & validation
Fig. 8 U.S. cancer biopsy market driver impact
Fig. 9 External factors driving the demand for cancer biopsy
Fig. 10 U.S. cancer biopsy market restraint impact
Fig. 11 SWOT analysis
Fig. 12 Porter’s five forces analysis
Fig. 13 Key driving factors of biopsy costs
Fig. 14 U.S. expenditures for cancer by payment source, 2014
Fig. 15 U.S. expenditures for cancer by payment source, 2018
Fig. 16 U.S. expenditures for cancer by type of service, 2014
Fig. 17 U.S. expenditures for cancer by type of service, 2014 Vs 2018 (USD Billion)
Fig. 18 U.S. cancer management expenditure
Fig. 19 U.S. cancer biopsy market: type outlook and key takeaways
Fig. 20 U.S. cancer biopsy market: type movement analysis
Fig. 21 Tissue biopsy vs liquid biopsy: comparative analysis
Fig. 22 U.S. cancer fine-needle aspiration (FNA) biopsy market estimates and forecasts, 2017 - 2028 (USD Million)
Fig. 23 U.S. cancer fine-needle aspiration (FNA) biopsy market estimates and forecasts for pharma - use, 2017 - 2028 (USD Million)
Fig. 24 U.S. cancer fine-needle aspiration (FNA) biopsy market estimates and forecasts for clinical - use, 2017 - 2028 (USD Million)
Fig. 25 U.S. cancer core needle biopsy market estimates and forecasts, 2017 - 2028 (USD Million)
Fig. 26 U.S. cancer core needle biopsy market estimates and forecasts for pharma - use, 2017 - 2028 (USD Million)
Fig. 27 U.S. cancer core needle biopsy market estimates and forecasts for clinical - use, 2017 - 2028 (USD Million)
Fig. 28 U.S. cancer surgical biopsy market estimates and forecasts, 2017 - 2028 (USD Million)
Fig. 29 U.S. cancer surgical biopsy market estimates and forecasts for pharma - use, 2017 - 2028 (USD Million)
Fig. 30 U.S. cancer surgical biopsy market estimates and forecasts for clinical - use, 2017 - 2028 (USD Million)
Fig. 31 U.S. skin biopsy /punch cancer biopsy market estimates and forecasts, 2017 - 2028 (USD Million)
Fig. 32 U.S .skin biopsy /punch cancer biopsy market estimates and forecasts for pharma - use, 2017 - 2028 (USD Million)
Fig. 33 U.S. skin biopsy /punch cancer biopsy market estimates and forecasts for clinical - use, 2017 - 2028 (USD Million)
Fig. 34 U.S. cancer biopsy market estimates and forecasts for other types, 2017 - 2028 (USD Million)
Fig. 35 U.S. other types cancer biopsy market estimates and forecasts for pharma - use, 2017 - 2028 (USD Million)
Fig. 36 U.S. other types cancer biopsy market estimates and forecasts for clinical - use, 2017 - 2028 (USD Million)
Fig. 37 Cancer biopsy market: site (organ) outlook and key takeaways
Fig. 38 Cancer biopsy market: site (organ) movement analysis
Fig. 39 U.S. cancer biopsy market estimates and forecasts for breast, 2017 - 2028 (USD Million)
Fig. 40 U.S. cancer biopsy market estimates and forecasts for thyroid, 2017 - 2028 (USD Million)
Fig. 41 U.S. cancer biopsy market estimates and forecasts for uterus & cervix, 2017 - 2028 (USD Million)
Fig. 42 U.S. cancer biopsy market estimates and forecasts for lung, 2017 - 2028 (USD Million)
Fig. 43 U.S. cancer biopsy market estimates and forecasts for prostate, 2017 - 2028 (USD Million)
Fig. 44 U.S. cancer biopsy market estimates and forecasts for bladder, 2017 - 2028 (USD Million)
Fig. 45 U.S. cancer biopsy market estimates and forecasts for kidney, 2017 - 2028 (USD Million)
Fig. 46 U.S. cancer biopsy market estimates and forecasts for liver, 2017 - 2028 (USD Million)
Fig. 47 U.S. cancer biopsy market estimates and forecasts for pancreas, 2017 - 2028 (USD Million)
Fig. 48 U.S. cancer biopsy market estimates and forecasts for other sites, 2017 - 2028 (USD Million)
Fig. 49 U.S. cancer biopsy market: application outlook and key takeaways
Fig. 50 U.S. cancer biopsy market: application movement analysis
Fig. 51 U.S. cancer biopsy market estimates and forecasts for screening & monitoring, 2017 - 2028 (USD Million)
Fig. 52 U.S. cancer biopsy market estimates and forecasts for diagnostics, 2017 - 2028 (USD Million)
Fig. 53 U.S. cancer biopsy market estimates and forecasts for investigational & translational research, 2017 - 2028 (USD Million)
Fig. 54 U.S. cancer biopsy market estimates and forecasts for pharma & biopharma discovery & development, 2017 - 2028 (USD Million)

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.